Loading...
Akero Therapeutics, Inc.
AKRO•NASDAQ
Healthcare
Biotechnology
$50.56
$0.05(0.10%)
Akero Therapeutics, Inc. (AKRO) Financial Performance & Income Statement Overview
Review Akero Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-65.11%
↓ 65.11%
Net Income Growth
-66.09%
↓ 66.09%
Operating Cash Flow Growth
-58.29%
↓ 58.29%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-31.98%
↓ 31.98%
ROIC
-27.51%
↓ 27.51%
Akero Therapeutics, Inc. (AKRO) Income Statement & Financial Overview
Review Akero Therapeutics, Inc.'s (AKRO) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $1000.00 | $1000.00 |
| Gross Profit | $0.00 | $0.00 | -$1000.00 | -$1000.00 |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $69.29M | $72.23M | $55.32M | $50.65M |
| SG&A Expenses | $8.73M | $9.47M | $10.42M | $9.30M |
| Operating Expenses | $78.03M | $81.70M | $65.74M | $59.95M |
| Total Costs & Expenses | $78.03M | $81.70M | $65.74M | $59.95M |
| Interest Income | $9.20M | $10.24M | $10.98M | $7.60M |
| Interest Expense | $1.20M | $1.25M | $1.23M | $991000.00 |
| Depreciation & Amortization | $15000.00 | $1000.00 | $1000.00 | $1000.00 |
| EBITDA | -$68.81M | -$71.46M | -$54.76M | -$52.35M |
| EBITDA Ratio | ||||
| Operating Income | -$78.03M | -$81.70M | -$65.74M | -$59.95M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $8.001M | $9.00M | $9.75M | $6.61M |
| Income Before Tax | -$70.02M | -$72.70M | -$55.99M | -$53.34M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$42276.00 |
| Net Income | -$70.02M | -$72.70M | -$55.99M | -$53.34M |
| Net Income Ratio | ||||
| EPS | -$0.99 | -$1.05 | -$0.81 | -$0.90 |
| Diluted EPS | -$0.99 | -$1.05 | -$0.81 | -$0.90 |
| Weighted Avg Shares Outstanding | $70.57M | $69.44M | $69.16M | $59.31M |
| Weighted Avg Shares Outstanding (Diluted) | $70.57M | $69.44M | $69.16M | $59.31M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan